PALO ALTO, Calif., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be presenting at the 35th Annual Cowen and Company Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA. Ocera’s presentation is scheduled for Monday, March 2, 2015 at 4:50 PM ET in Salon B, 4th floor, and will be followed by a breakout session in Salon A.
A live audio webcast of the presentation will be available in the “Investors” section of Ocera’s website, www.ocerainc.com. A replay of the presentation will be available for 30 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
Susan Sharpe
Ocera Therapeutics, Inc.
contact@ocerainc.com
919-328-1109
Help employers find you! Check out all the jobs and post your resume.
